MMP9 gene expression inhibitor, iv type collagen degradation inhibitor, and topical composition for skin
Patent Information
- Application Number
- JP2023088609
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-30
- Publication Date
- 2024-12-12
AI Technical Summary
【0008】 本発明により、MMP9遺伝子の発現を抑制する成分が提供される。また、IV型コラーゲンの分解を抑制する成分が提供される。
Smart Images

Figure 2024171544000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to an agent for suppressing the expression of matrix metalloproteinase-9 (hereinafter referred to as MMP9) gene. [Background technology]
[0002] MMP is a general term for extracellular matrix degrading enzymes produced by fibroblasts, endothelial cells, cancer cells, etc., and degrades extracellular matrices such as collagen, gelatin, elastin, and laminin 5, which is a major component of basement membrane. For example, MMP9, which belongs to MMP, is an enzyme that degrades type IV collagen present in basement membrane. Substances that have inhibitory activity against MMP9 are expected to have an effect of suppressing angiogenesis and cancer metastasis in cancer tissues, and are considered to be useful for preventing and treating cancer diseases. Furthermore, inhibition of MMP9 is useful not only for cancer diseases, but also for preventing, treating, and improving diseases and conditions caused by the activation of the gene encoding MMP9 (MMP9 gene), such as ulcer formation, chronic rheumatoid arthritis, and wrinkles and sagging skin. Therefore, a component with excellent MMP9 inhibitory activity is desired.
[0003] On the other hand, the use of the Angelica keiskei extract used in the present invention has been reported, for example, as a hyaluronic acid production promoter (Patent Document 1). [Prior art documents] [Patent documents]
[0004] [Patent Document 1] Patent Publication No. 2022-167197 Summary of the Invention [Problem to be solved by the invention]
[0005] However, it is not known that Angelica keiskei extract inhibits the expression of MMP9 gene. Therefore, the present invention aims to provide a technique for inhibiting the expression of MMP9 gene. In addition, the present invention aims to provide a technique for inhibiting the degradation of type IV collagen. [Means for solving the problem]
[0006] As a result of intensive research conducted by the present inventors to solve the above problems, they discovered that Angelica keiskei extract has the effect of suppressing the expression of the MMP9 gene, and further discovered that it can suppress the degradation of type IV collagen, thereby completing the present invention.
[0007] That is, the present invention is as follows. [1] An MMP9 gene expression inhibitor containing Angelica keiskei extract. [2] An agent that inhibits the breakdown of type IV collagen, containing Angelica keiskei extract. [3] A composition for external application to the skin containing Angelica keiskei extract for inhibiting MMP9 gene expression or inhibiting the degradation of type IV collagen. Effect of the Invention
[0008] The present invention provides a component that suppresses the expression of the MMP9 gene and a component that suppresses the degradation of type IV collagen. [Brief description of the drawings]
[0009] [Figure 1] 2 is a graph showing the expression level of MMP9 gene in epidermal keratinocytes when incubated with or without the addition of Angelica keiskei extract. The expression level is the relative level when the solvent control is taken as 100. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0010] The MMP9 gene expression inhibitor and type IV collagen degradation inhibitor of the present invention contain Angelica keiskei extract as an active ingredient. Angelica keiskei extract is an extract of Angelica keiskei (scientific name: Angelica keiskei) of the Apiaceae family. Angelica keiskei grows naturally in the Boso Peninsula, Izu Peninsula, and other areas, and can be easily obtained from these areas. Examples of parts of Angelica keiskei that can be used as a raw material for extracting Angelica keiskei include leaves, stems, flowers, buds, fruits, peels, pits, roots, and mixtures thereof, and preferably leaves or stems.
[0011] The above-mentioned extract is a general term not only for the extract itself, but also for a fraction of the extract, a purified fraction, an extract or fraction, or a product obtained by removing the solvent from the purified product. The extract may be any extract that is normally used in skin external preparations such as cosmetics and pharmaceuticals, or in compositions for oral ingestion, and may be extracted from a plant body by a conventional method.
[0012] As the extraction solvent, one or more selected from polar solvents such as water, alcohols such as ethanol, isopropyl alcohol, butanol, polyhydric alcohols such as 1,3-butanediol, polypropylene glycol, ketones such as acetone, methyl ethyl ketone, ethers such as diethyl ether, tetrahydrofuran, etc. are preferably used.
[0013] A specific example of the extraction method is to add 1 to 30 parts by mass of a solvent to 1 part by mass of the part of the plant body or the like used for extraction or its dried matter, immerse the part for several days at room temperature or several hours at a temperature near the boiling point, cool to room temperature, and then remove insoluble matter and / or the solvent as desired, and fractionate and purify the part by column chromatography or the like.
[0014] Angelica keiskei extract has the effect of suppressing the expression of the MMP9 gene, that is, Angelica keiskei extract is an active ingredient of an MMP9 gene expression inhibitor.
[0015] The MMP9 gene expression suppression effect can be confirmed by the fact that the expression level of the MMP9 gene in cells to which the MMP9 gene expression suppressor has been added is smaller than that in cells to which the MMP9 gene expression suppressor has not been added, usually 90% or less, preferably 80% or less, more preferably 70% or less. The expression level of the MMP9 gene can be measured, for example, by carrying out PCR using a DNA fragment having a sequence that specifically binds to the sequence of the MMP9 gene as a primer, and measuring the amount of mRNA. In addition, for example, the amount of protein encoded by the MMP9 gene can be quantitatively measured by a conventional method to determine the expression level of the MMP9 gene.
[0016] The cells in which the expression of the MMP9 gene is suppressed by the MMP9 gene expression inhibitor of the present invention are not particularly limited as long as they are cells that originally express the MMP9 gene, and examples of such cells include epidermal keratinocytes, dermal fibroblasts, and cancer cells.
[0017] Since MMP9 is an enzyme that breaks down type IV collagen, the decomposition of type IV collagen can be inhibited by inhibiting the expression of MMP9 gene.Therefore, Angelica keiskei extract has the effect of inhibiting the decomposition of type IV collagen.That is, Angelica keiskei extract is an active ingredient of the type IV collagen decomposition inhibitor.
[0018] Type IV collagen is a collagen present in the basement membrane and plays a role in connecting the epidermis and dermis of the skin. Therefore, the type IV collagen degradation inhibitor of the present invention inhibits collagen degradation in the basement membrane. It is preferable that the composition suppresses the degradation of type IV collagen.
[0019] The inhibitory effect on type IV collagen degradation can be confirmed, for example, by the fact that the amount of type IV collagen in cells to which the inhibitor for type IV collagen degradation has been added is greater than the amount of type IV collagen in cells to which the inhibitor has not been added, usually 110% or more, preferably 120% or more, and more preferably 130% or more. The amount of type IV collagen can be measured, for example, by measuring the amount of type IV collagen present using ELISA or Western blotting. .
[0020] The route of administration of the MMP9 gene expression inhibitor or type IV collagen degradation inhibitor of the present invention (hereinafter also referred to as "the agent of the present invention") is not particularly limited, and may be transdermal, oral, nasal, intravenous injection, etc., but transdermal administration is preferred. Here, "administration" may be replaced with "ingestion". The dosage of the agent of the present invention is not particularly limited, but taking into consideration the desired effect and safety, it is preferable to take 0.3 to 300 μg / day in solid form as the total amount of Angelica keiskei extract once or in several divided doses. In addition to taking it once, it is also preferable to take it continuously or intermittently for several weeks to several months.
[0021] In another embodiment, the present specification also provides a composition for external application to the skin, which contains Angelica keiskei extract and is used to inhibit the expression of MMP9 gene or inhibit the degradation of type IV collagen. The embodiment of the skin topical composition of the present invention is not particularly limited as long as it is applied to the skin, but preferred examples include cosmetics (including quasi-drugs) and medicines, and more preferred are cosmetics. Examples of cosmetics include face washes, cleansing agents, lotions, beauty essences, milky lotions, creams, gels, sun care products, etc. The site to which the topical skin composition of the present invention is applied is not particularly limited, but is usually the face, limbs, neck, and décolleté.
[0022] Examples of the dosage form of the external skin composition include, but are not limited to, lotion dosage forms, emulsion dosage forms such as milky lotion and cream, oil dosage forms, gel dosage forms, packs, cleansers, and the like. The composition for external use on the skin may be either a leave-on type or a leave-off type.
[0023] The content of Angelica keiskei extract in the composition for external use on skin of the present invention is preferably 0.00001 to 0.09 mass %, more preferably 0.00005 to 0.03 mass %, and even more preferably 0.0001 to 0.003 mass %, calculated as solid matter based on the total mass of the composition. By setting the content within the above range, the desired effect can be easily obtained and the freedom in formulation design can be ensured. The above content can be appropriately adjusted depending on the above-mentioned administration route and the form of the composition to be contained.
[0024] In producing the composition for external use on the skin of the present invention, any ingredients that are usually used in the formulation of cosmetics, quasi-drugs, pharmaceuticals and the like can be blended. Examples of such optional components include hydrocarbons such as squalane, petrolatum, and microcrystalline wax; esters such as jojoba oil, carnauba wax, and octyldodecyl oleate; triglycerides such as olive oil, beef tallow, and coconut oil; fatty acids such as stearic acid, oleic acid, and retinoic acid; higher alcohols such as oleyl alcohol, stearyl alcohol, and octyldodecanol; anionic surfactants such as sulfosuccinate esters and sodium polyoxyethylene alkyl sulfates; amphoteric surfactants such as alkyl betaine salts; cationic surfactants such as dialkyl ammonium salts; sorbitan fatty acid esters, fatty acid monoglycerides, and polyoxyethylene adducts thereof; nonionic surfactants such as polyoxyethylene alkyl ethers and polyoxyethylene fatty acid esters; Polyhydric alcohols such as ethylene glycol, glycerin, 1,3-butylene glycol, thickeners / gelling agents, antioxidants, UV absorbers, colorants, preservatives, powders, etc. can be added as desired. EXAMPLES
[0025] The present invention will be described in more detail below with reference to examples. However, the present invention is not limited to the following examples as long as it does not depart from the gist of the present invention.
[0026] <Reference example 1> The Angelica keiskei extract was prepared according to the following procedure. The dried leaves and roots of Angelica keiskei (Apricot family, Angelica keiskei genus) were crushed, and 10 times the amount of 30% 1,3-butylene glycol aqueous solution was added, and the solution extracted by refluxing was freeze-dried to powder. The powder was then dissolved in 30% 1,3-butylene glycol aqueous solution.
[0027] <Test Example 1> Examination of the effect of Angelica keiskei extract on MMP9 gene expression in epidermal keratinocytes Normal human epidermal keratinocytes (NHEK, newborn, male, Caucasian) stored at -150℃ were put to sleep and placed in a 37℃ / 5% CO2 environment for 5 days. NHEK were harvested and cultured at 8.0 × 10 4 The cells were diluted with HUMedia-KG2 (Kurabo) NHEK medium to give a total of 100 cells / mL. 500 μL of the medium was added to each well, and NHEKs were seeded at 500 μL per well (4.0 × 10 4 The cells were cultured overnight at 37°C and 5% CO2 (cells / well). After culture, the medium was removed and replaced with NHEK medium containing Angelica keiskei extract adjusted with 1,3-butylene glycol aqueous solution so that the solid concentration of Angelica keiskei extract was 0.05% by mass, or with NHEK medium containing 1,3-butylene glycol aqueous solution instead of Angelica keiskei extract, and cultured for another 48 hours. After culture, the cells were washed with PBS(-) and collected, and RNA was extracted with QIAcube (QIAGEN) using QIAshredder and RNeasy Mini Kit (QIAGEN). The extracted RNA was purified using the SuperScript VILO cDNA Synthesis Kit (Invitrogen). The cDNA was generated using SYBR (QIAGEN) and analyzed using QuantStudio 7 (Applied Biosystems). The expression levels of each MMP9 gene were analyzed by RT-qPCR. , the β-Actin gene was used. The Angelica keiskei extract prepared by the method of Reference Example 1 was used.
[0028] FIG. 1 shows the mRNA expression level of the MMP9 gene in epidermal keratinocytes to which Angelica keiskei extract was added, expressed as a relative value when the mRNA expression level of the MMP9 gene in epidermal keratinocytes of the solvent control (control) was set at 100. In epidermal keratinocytes to which Angelica keiskei extract was added, the mRNA expression level of MMP9 gene was found to be significantly decreased compared to the control. This result indicates that Angelica keiskei extract has an effect of suppressing MMP9 gene expression. In addition, since MMP9 is an enzyme that breaks down type IV collagen, it is speculated that Angelica keiskei extract inhibits the breakdown of type IV collagen by suppressing the expression of MMP9 gene. [Industrial Applicability]
[0029] Since the MMP9 gene expression inhibitor of the present invention has an excellent MMP9 gene expression inhibitory effect, it can be suitably used as one component of cosmetics, etc. In addition, the MMP9 gene expression inhibitor of the present invention can also be used as an inhibitor of type IV collagen degradation.
Claims
1. An MMP9 gene expression inhibitor containing Angelica keiskei extract.
2. A type IV collagen decomposition inhibitor containing Angelica keiskei extract.
3. A composition for external application to the skin, which contains Angelica keiskei extract and is used to inhibit MMP9 gene expression or inhibit the degradation of type IV collagen.
Citation Information
Patent Citations
Food composition
JP2005052085A
Agent promoting laminin 5 production, agent normalizing dermal basement membrane, and agent promoting recovery of skin lesion
JP2009040757A
Matrix metalloprotease (MMP) production inhibitor
JP2011178747A
Pharmaceutical composition containing chalcone or its derivatives for matrix metalloproteinase inhibitory activity
WO2003037315A1
Hyaluronic acid production promoter, epidermal hyaluronic acid production promoter, and dermal hyaluronic acid production promoter
JP2022167197A
